help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tannenbaum, G. S.
Right arrow Articles by Beaudet, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tannenbaum, G. S.
Right arrow Articles by Beaudet, A.

Endocrinology, Vol 127, 2551-2560, Copyright © 1990 by Endocrine Society


ARTICLES

Cysteamine-induced enhancement of growth hormone-releasing factor (GRF) immunoreactivity in arcuate neurons: morphological evidence for putative somatostatin/GRF interactions within hypothalamus

GS Tannenbaum, GF McCarthy, P Zeitler and A Beaudet
Department of Pediatrics, McGill University, Montreal, Quebec, Canada.

The episodic secretion of GH is regulated through the reciprocal release into the hypophyseal portal circulation of two hypothalamic peptides, SRIF and GRF. Recent physiological evidence suggests that, in addition to exerting their well documented opposite actions at the level of the anterior pituitary, SRIF and GRF may interact within the central nervous system to modulate GH secretion. The aim of the present study was to provide morphological evidence to support the concept that SRIF exerts an influence on the GRF-containing neuronal system within the hypothalamus. To accomplish this, we used the thiol agent cysteamine (CSH; 300 mg/kg sc) to manipulate endogenous hypothalamic SRIF and examined its effects on the immunoreactivity and mRNA content of GRF-containing arcuate (ARC) neurons, using immunohistochemistry and semi-quantitative in situ hybridization, respectively. Hypothalamic SRIF content and pulsatile GH secretion were also monitored. CSH treatment reduced hypothalamic immunoreactive SRIF concentrations (to 60% of vehicle-injected control values) and severely suppressed the spontaneous surges of GH release (mean GH peak amplitude: 24.2 +/- 2.7 vs. 168.0 +/- 27.8 ng/ml in H2O-injected controls; P less than 0.001). CSH treatment also resulted in a striking increase in the number and labeling density of GRF-immunoreactive cells detected in the ARC nucleus. Cell counts revealed an overall 126% increase, over controls, in the mean number of detectable GRF-positive ARC neurons. This increase (P less than 0.01) was apparent over all rostrocaudal levels of the ARC nucleus, but was most pronounced within the caudal tier. Administration of CSH also produced a massive qualitative increase in the intensity and extent of staining of GRF-positive terminal elements in the external zone of the median eminence. Conversely, CSH treatment resulted in a decline in GRF mRNA-associated signal in cells of the ARC nucleus, with this decline being most evident in the caudal third of the nucleus. The finding of an increase in GRF immunoreactivity in ARC neurons in association with a decrease in plasma GH, as well as with a decline in relative GRF mRNA content, suggests that CSH leads to an overall decrease in GRF release from the median eminence. These results provide morphological evidence to support the concept of a SRIF- mediated central influence on the GRF-containing ARC neuronal system. Such central regulation of GRF by SRIF may be an important mechanism in the physiological control of pulsatile GH secretion.


This article has been cited by other articles:


Home page
Biol. Reprod.Home page
H. H. Van Vugt, H. J.M. Swarts, B. J.M. Van de Heijning, and E. M. Van der Beek
Centrally Applied Somatostatin Inhibits the Estrogen-Induced Luteinizing Hormone Surge via Hypothalamic Gonadotropin-Releasing Hormone Cell Activation in Female Rats
Biol Reprod, September 1, 2004; 71(3): 813 - 819.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
I. Hata, Y. Shigematsu, Y. Ohshima, H. Tsukahara, K. Fujisawa, M. Hiraoka, H. Nakamura, H. Masutani, J. Yodoi, F. Kotsuji, et al.
Involvement of thioredoxin in the regulation of growth hormone secretion in rat pituitary cell cultures
Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E269 - E274.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
C. D. McMahon, L. T. Chapin, K. J. Lookingland, R. P. Radcliff, and H. A. Tucker
Feeding Reduces Activity of Growth Hormone-Releasing Hormone and Somatostatin Neurons
Experimental Biology and Medicine, February 1, 2000; 223(2): 210 - 217.
[Abstract] [Full Text]


Home page
Exp. Biol. Med.Home page
C. J. Phelps and D. L. Hurley
Pituitary Hormones as Neurotrophic Signals: Update on Hypothalamic Differentiation in Genetic Models of Altered Feedback
Experimental Biology and Medicine, October 2, 1999; 222(1): 39 - 58.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Wagner, S. R. Caplan, and G. S. Tannenbaum
Genesis of the ultradian rhythm of GH secretion: a new model unifying experimental observations in rats
Am J Physiol Endocrinol Metab, December 1, 1998; 275(6): E1046 - E1054.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. R. Baumbach, T. A. Carrick, M. H. Pausch, B. Bingham, D. Carmignac, I. C. A. F. Robinson, R. Houghten, C. M. Eppler, L. A. Price, and J. R. Zysk
A Linear Hexapeptide Somatostatin Antagonist Blocks Somatostatin Activity In Vitro and Influences Growth Hormone Release in Rats
Mol. Pharmacol., November 1, 1998; 54(5): 864 - 873.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society